BRISTOL-MYERS SQUIBB CO (BMY) Stock News
NYSE:BMY - New York Stock Exchange, Inc. - US1101221083 - Common Stock - Currency: USD
BMY Latest News, Press Relases and Analysis
Top S&P500 movers in Friday's session
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
What's going on in today's session: S&P500 movers
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Don’t Miss These 4 Stocks With Explosive Dividend Yields
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play?
BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.
Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income?
Bristol-Myers Squibb Company (NYSE:BMY) is included among the 10 Best Passive Income Stocks to Buy Now. On June 17, the company declared a quarterly dividend of $0.62 per share, which was consistent with its previous dividend. Overall, it has raised its payouts for 16 consecutive years and has delivered uninterrupted payouts for 93 years in […]
What's going on in today's session: S&P500 gap up and gap down stocks
Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.
Recent Agreements Set To Bolster BioNTech SE (BNTX)’s Oncology Arm
BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases. On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s […]
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
Warren Buffett Owns 9 Ultra-High-Yield Dividend Stocks. Here's the Best of the Bunch.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
Incyte Corporation (NASDAQ:INCY) is one of the top 10 S&P 500 winners of the day that Jim Cramer highlighted. Cramer appreciated the new CEO of the company, as he commented: “We then have Incyte. That’s a biotech company. It just got a new CEO, Bill Meury. He’s an industry veteran, known as a deal maker. […]
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.29% dividend yield, strong profitability, and a reasonable valuation, making it a compelling choice for dividend investors.
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst
Bristol-Myers Squibb Company (NYSE:BMY) ranks among the top stocks for an early retirement portfolio. On June 12, Cantor Fitzgerald maintained its price target of $55 and its rating of Neutral for Bristol-Myers Squibb Company (NYSE:BMY). The company’s Cobenfy’s ADEPT-2 top-line data in Alzheimer’s Disease Psychosis is anticipated in 2025, possibly as early as the second […]